Psychiatr. praxi. 2015;16(2):56-59

Adverse effects of antipsychotic treatment

prof.RNDr.Ludmila Kameníková, DrSc.1, Mgr.Jan Pomykacz2, prof.Dr.Hassan Farghali, DrSc.1
1 1. LF UK a VFN, Farmakologický ústav, Praha
2 Psychiatrická nemocnice Bohnice, ústavní lékárna, Praha

The long term use of antipsychotics with several adverse effects is addressed. The article enumerates these adverse effects to emphasize

the importance of thorough treatment according to the overall physical and psychic conditions of the patient with the assessment of

benefit/risk ratio of the given agent.

Keywords: antipsychotics, adverse effects, extrapyramidal symtoms

Published: May 18, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kameníková L, Pomykacz J, Farghali H. Adverse effects of antipsychotic treatment. Psychiatr. praxi. 2015;16(2):56-59.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 4556: 789-796. Go to original source... Go to PubMed...
    2. Kane J, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline serie. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary and summary. J Clin Psychiatry 2003; 64(suppl. 12): 5-19.
    3. Lieberman JA, Stroup TS, McEvoy JP, Schwarz MS, et al. Effectiveness of antipsychotic drugs in patiens with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223. Go to original source... Go to PubMed...
    4. Jones PB, Barnes TR, Davies L, Dunn GG, et al. Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost utilityof the latest antipsychotic drugs in schizophrenia study. Arch Gen Psychiatry 2006; 63: 1079-1087. Go to original source... Go to PubMed...
    5. Maršálek M. Extrapyramidové poruchy. In Seifertová D, Praško J, Höschl C. (Eds). Postupy v léčbě psychotických poruch. Praha: Academia Medica Pragensia, 2004; p. 387-406.
    6. Přikryl R. Léčba atypickými antipsychotiky a jejich volba podle spektra nežádoucích účinků. Psychiat. pro Praxi 2009; 10: 22-25.
    7. DeBattista Ch. Antipsychotic Agents & Lithium in Basic & Clinical Pharmacology. Katzung Ed. BG, Trevor AJ, 13th Edition LANGE, 2015: 490-509.
    8. Rang and Dale's Pharmacology. Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Seventh Edition, Antipsychotic drugs, 2012: 553-563. Go to original source...
    9. Downing LJ, Caprio TV, Lyness J. Geriatric psychiatry review: differential diagnosis and treatment of the 3 D's-delirium, dementia, and depression. Curr Psychiatry Rep 2013; 15: 365-375. Go to original source... Go to PubMed...
    10. Riggs AR. Antipsychotic use for behavioral and psychological symptoms of dementia. US Pharm 2013; 38: HS8-HS14.
    11. Holmerová I, Rusina R, Jirák R. Rizika a nevýhody podávání antipsychotik v dlouhodobé péči u pacientů s demencí. Psychiatr. pro Praxi 2014; 15: 58-61.
    12. Department of Health and Human Services Office of the Inspector General. Medicare atypical antipsychotic drug claims for elderly nursing home residents. http://oig.hhs.gov/oei/reports/oei-07-08-00150.pdf. Accessed July 28, 2013.
    13. Kršiak M. Antipsychotika (neuroleptika) v knize Základní a aplikovaná farmakologie (D. Lincová a H. Farghali a sp.) 2007: Galen, str. 182.
    14. Huybrechts KF, Schneeweiss S, Bernard T, Olfson M, et al.:Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc 2012; 60: 420-429. Go to original source... Go to PubMed...
    15. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. Brit Med J 2008; 337: 1227. Go to original source... Go to PubMed...
    16. Steinberg M, Lyketsos CG. Atypical antipsychotic use in patiens with dementia: managing safety concerns. Am J Psychiatry 2012; 169: 901-906. Go to original source... Go to PubMed...
    17. Kales HC, Kin HM, Zivin K, Valenstein M, et al. Risk of mortality among individual antipsychotics in patiens with dementia. Am J Psychiatry 2012; 169: 71-79. Go to original source... Go to PubMed...
    18. Pálenský V, Přikryl R, Floriánová A, Weislamplová M, Kašperek T, Synek O, Češková E, Špinar E. Atypická antipsychotika a prolongace QTc intervalu. Čes a slov Psychiatr 2007; 103: 325-328.
    19. Kutcher S, Brooks SJ, Gardner DM, et al. Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders. Neuropsychiatr Dis Treat 2005; 1: 89-108. Go to original source... Go to PubMed...
    20. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. New Engl J Med 2009; 360: 225-235. Go to original source... Go to PubMed...
    21. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21: 911-936. Go to original source... Go to PubMed...
    22. Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994; 44: 2247-2249. Go to original source... Go to PubMed...
    23. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis Lancet 2003; 361: 1581-1589. Go to original source... Go to PubMed...
    24. Kramer MS, Gorkin R, DiJohnson C. Treatment of neuroleptic-induced akathisia with propranolol: a controlled replication study. Hillside J Clin Psychiatry 1989; 11: 107-119.
    25. Dursun S, Haddad PM, Barnes TR. Extrapyramidal syndromes. In: Haddad PM, Dursun S, Deakin B, eds. Adverse Syndromes and Psychiatric Drugs. New York, N.Y.: Oxford University Press; 2004. Go to original source...
    26. El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Wieser K. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2006; CD000458. Go to original source... Go to PubMed...
    27. Soares KV, McGrath JJ. Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. 2000; CD000204. Go to original source...
    28. Maglione M, Ruelaz Maher A, Hu J, Wang Z, et al. Off-label use of atypical antipsychotics: an update/Internet/. Rockville M.D.: Agency for Healthcare Research and Quality, September 2011.
    29. Chew ML, Mulsant BH, Pollock BG, Lehman ME, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006; 88: 63-72. Go to original source... Go to PubMed...
    30. Bryden KE, Kopala LC. Body mass index increase of 58 % associated with olanzapine. Am J Psychiatry 1999; 156: 1835-1836. Go to original source... Go to PubMed...
    31. Gardner DM, Baldessarini RJ, Waraich P: Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172: 1703-1711. Go to original source... Go to PubMed...
    32. Ramaswamy K, Kozma CM, Nasrallah H. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine. Drug Saf 2007; 30: 589-599. Go to original source... Go to PubMed...
    33. Koro CE, Meyer JM. Atypical antipsychotic therapy and hyperlipidemia: a review. Essent Psychopharmacol 2005; 6: 148-157. Go to PubMed...
    34. Newcomer J.W. Metabolit considerations in the use of antipsychotic medications. J Clin Psychiatry 2007; 68: 20-27. Go to original source...
    35. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patiens treated with risperidone. J Clin Psychopharmacol 1999; 19: 57-61. Go to original source... Go to PubMed...
    36. Wallace M. Real progress-the patient's perspective. Int Clin Psychopharmacol 2001; 16: S21-S24. Go to original source... Go to PubMed...
    37. Wirshing DA, Pierre JM, Marder SR, Saunders CS, Wirshing WC. Sexual side effects of novel antipsychotic medications. Schizophr Res 2002; 56: 25-30. Go to original source... Go to PubMed...
    38. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patiens with a history of schizophrenia. Br J Psychiatry 2007; 190: 129-134. Go to original source... Go to PubMed...
    39. Huguet B, Fongue J, Chiche L, Gilly L, Pastor MJ, Michelet P, Rouby F. Neuroleptic associated hypothermia: A new case report and study of spontaneous reports to the French pharmacovigilance network. Revue de Medecine Interne 2015; 36: 124-126. Go to original source... Go to PubMed...
    40. Lippincott's Illustrated Reviews Pharmacology 5th edition (Ed. R. A. Harvey) 2012, Antipsychotic Drugs 161-168.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.